EP: 6.The EMERALD Trial: Elacestrant in Patients with HR+, HER2- Advanced Breast Cancer EP: 7.The TROPION-Breast01 Trial: Datopotamab Deruxtecan in HR+, HER2- Breast Cancer EP: 8.Approaches to Treatment Decision-Making and Sequencing for HR+, HER2- Metastatic Breast Cancer EP:...
Dr Bardia discusses the mechanism of action of elacestrant, how elacestrant compares to other SERDS, and introduces the EMERALD trial. EP: 1.An Introduction to ER+/HER2- mBC and Current Treatment Options EP: 2.Biomarker Testing in Patients With ER+/HER2- mBC ...
Elacestrant prolonged progression-free survival in patients with pretreated, ER-positive, HER2-negative breast cancer. Breast Cancer: © SciePro - stock.adobe.com A post hoc subgroup analysis from the phase 3 EMERALD trial (NCT03778931) showed that elacestrant (Orserdu) improved progression...
Elacestrant is a novel, nonsteroidal, orally bioavailable selective estrogen receptor degrader (SERD) that has demonstrated activity in patients with estrogen receptor (ER)-positive/HER2-negative breast cancer previously treated with endocrine therapies including fulvestrant and/or CDK 4/6 inhibitor ...
Kevin Kalinsky, MD, MS, gives an overview of recent data from the EMERALD trial investigating elacestrant in patients with ER+/HER2- advanced breast cancer. EP: 1.Testing for ESR1 Mutations in Breast Cancer EP: 2.Overcoming Challenges in Biomarker Testing in Breast Cancer EP: 3.PADA-1 ...
最新的EMERALD 3期试验事后分析评估了elacestrant在患有携带ESR1突变的肿瘤的内分泌敏感人群(持续接受CDK4/6抑制剂治疗至少12个月)中的应用情况。 分析显示,在考察的亚组中(包括已发生骨、肝和/或肺转移的患者、携带PIK3CA和TP53等常见伴随突变的患者,以及HER2低表达的患者),其无进展生存期均取得了显著的临床改善...
- With these results, elacestrant became the first oral SERD to demonstrate higher efficacy than fulvestrant in a pivotal trial - Elacestrant was well tolerated and can become standard of care in this patient population FLORENCE, ItalyandBOSTON,Dec. 9, 20...
Elacestrant is a novel, oral selective ER degrader that demonstrated activity in early studies. METHODS This randomized, open-label, phase III trial enrolled patients with ER-positive/HER2-negative advanced breast cancer who had one-two lines of endocrine therapy, required pretreatment with a ...
Elacestrant is a novel, nonsteroidal, orally bioavailable selective estrogen receptor degrader (SERD)that has demonstrated activity in patients with estrogen receptor (ER)-positive/HER2-negative breast cancer previously treated with endocrine therapies including fulvestrant and/or CDK 4/6 inhibitor thera...
But the findings from the EMERALD trial, which led to the approval of ORSERDU® (elacestrant) for patients with ER-positive/HER2-negative ESR1-mutated metastatic breast cancer after disease progression on endocrine therapy,1 contribute to our understanding of second-line treatment ...